SynthesisJournal of clinical hypertension (Greenwich, Conn.)2025
Clinical and Biochemical Outcomes of Super-Selective Adrenal Artery Embolization in Primary Aldosteronism: A Systematic Review and Meta-Analysis.
Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This systematic review and meta-analysis study evaluated the clinical and biochemical efficacy of super-selective adrenal artery embolization (SAAE) in patients with primary aldosteronism (PA). The primary outcome was the change in office blood pressure, while secondary outcomes included changes in plasma aldosterone and serum potassium levels following the procedure. A systematic search of Embase, PubMed, Ovid, Web of Science, China National Knowledge Infrastructure, Wanfang, and SinoMed was conducted through December 14, 2024. Seventeen studies involving 650 patients (aged 28-65 years) with a median follow-up of 6 months were included. Meta-analysis, subgroup analysis, publication bias assessment, and sensitivity analysis were performed using RevMan 5.3 and R 4.2.3. The results showed that SAAE significantly reduced systolic (MD = -19.84 mmHg, 95% CI: -22.87 to -16.82 mmHg) and diastolic blood pressure (MD = -10.62 mmHg, 95% CI: -12.61 to -8.64 mmHg), lowered plasma aldosterone levels (MD = -90.99 pg/mL, 95% CI: -119.36 to -62.63 pg/mL), and increased serum potassium levels (MD = 0.59 mmol/L, 95% CI: 0.49-0.70 mmol/L). Subgroup analyses confirmed benefits in patients with both idiopathic hyperaldosteronism and aldosterone-producing adenoma. These findings support SAAE as an effective treatment for improving clinical outcomes and correcting biochemical abnormalities in PA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.